Post progression survival in glioblastoma: where are we?

Enrico Franceschi, Mario Ermani, Stefania Bartolini, Marco Bartolotti, Rosalba Poggi, Giovanni Tallini, Gianluca Marucci, Antonio Fioravanti, Alicia Tosoni, Raffaele Agati, Antonella Bacci, Eugenio Pozzati, Luca Morandi, Damiano Balestrini, Claudio Ghimenton, Girolamo Crisi, Alba A. Brandes

Research output: Contribution to journalArticle

Abstract

The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0–2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18–77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1–2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3–26.9 %). The median PPS was 8.6 months (95 % CI 7.4–9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3–72.9 %), PPS-9: 48.2 % (95 % CI 41.5–54.9 %) and PPS-12: 31.7 % (95 % CI 25.2–38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.

Original languageEnglish
Pages (from-to)399-404
Number of pages6
JournalJournal of Neuro-Oncology
Volume121
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • End points
  • Glioblastoma
  • Post-progression survival
  • Progression-free survival
  • Recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Post progression survival in glioblastoma: where are we?'. Together they form a unique fingerprint.

Cite this